Subcutaneous enoxaparin for outpatient anticoagulation therapy in a patient with an aortic valve replacement

Pharmacotherapy

Volumn 18, Issue 2 I, 1998, Pages 408-412

  Manley, Harold J ^a,b   Smith, Judith A ^c   Garris, Robert E ^a,b  

^a VA Healthcare Network Upstate New York   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN; WARFARIN;

AGED; ANTICOAGULATION; AORTA VALVE REPLACEMENT; ARTICLE; CASE REPORT; CONTUSION; COST CONTROL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; OUTPATIENT; PARTIAL THROMBOPLASTIN TIME; PROSTATE HYPERTROPHY; PROTHROMBIN TIME; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS; TRANSURETHRAL RESECTION;

AGED; ANTICOAGULANTS; AORTIC VALVE; BLOOD COAGULATION; ENOXAPARIN; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERNATIONAL NORMALIZED RATIO; MALE; OUTPATIENTS;

EID: 0031894203     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Rhône-Poulenc Rorer. Lovenox (enoxaparin sodium) injection package insert. Fort Washington, PA; 1996.
2. Levine M, Gent M, Hirsh J, et al. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334(11):677-81.
3. Huet Y, Gouault-Heilmann M. Low molecular weight heparin fraction PK 10169: a new therapeutic means for anticoagulant therapy? Haemostasis 1986;16(2):165-72.
4. Théry C, Simonneau G, Meyer G, et al. Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (fraxiparin) compared to intravenous unfractionated heparin in curative treatment of submassive pulmonary embolism: a dose ranging study. Circulation 1992;85(4):1380-9.
5. Smith RE, Townsend GE, Berry BR, Bowen T. Enoxaparin for unstable angina and ancrod for cardiac surgery following heparin allergy. Ann Pharmacother 1996;30(5):476-80.
6. Slocum MM, Adams JA, Teel R, Spadone DP, Silver D. Use of enoxaparin in patients with heparin induced thrombocytopenia syndrome. J Vasc Surg 1996;23(5):839-43.
7. Warkentin T, Levine M, Hirsh J, et al. Heparin-induced thrombocytopenia in patients with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332: 1330-5.
8. Rostoker G, Durand-Zaleski I, Petit-Phar M, et al. Prevention of thrombotic complications of the nephrotic syndrome by the low molecular weight heparin enoxaparin. Nephron 1995;69(1):20-8.
9. Kaaja R, Lehtovirta P, Venesmaa P, et al. Comparison of enoxaparin, a low molecular weight heparin, and unfractionated heparin, with or without dihydroergotamine, in abdominal hysterectomy. Eur J Obstet Gynecol Reprod Biol 1992;47(2):141-5.
10. Or R, Nagler A, Shpilberg O, et al. Low molecular weight heparin for prevention of veno-occlusive disease of the liver in bone marrow transplant patients. Transplantation 1996;61(7): 1067-71.
11. Reach I, Thebaud HE, Dupuy CA, et al. Optimisation de la dose d'enoxaparine (Lovenox®) dans la prevention de la coagulation des circuits d'hemodialyse: resultats d'une etude multicentrique. Nephrologie 1994;15(6):395-401.
12. Dulitzki M, Pauzner R, Langevitz P, Pras M, Manu A, Schiff E. Low molecular weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol 1996;83(3):380-3.
13. Simmonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low-molecular-weight heparin compared with continuous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993;153:1541-6.
14. Vongpatanasin W, Hillis D, Lange RA. Prosthetic heart valves. N Engl J Med 1996;335(6):407-15.
15. Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AGG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1995;108(4):371s-9.
16. Cannegieter S, Rosendale F, Wintzen A, van der Meer F, Vanderbroucke J, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-17.
17. Koopman MMW, Pradoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin at home. N Engl J Med 1996;334:682-7.
18. Charland SL, Tillman D, Davis DD, Beers A Jr, Koester B. The use of a low molecular weight heparin in the outpatient treatment of venous thrombosis [abstr]. Pharmacotherapy 1997;17(1):183.
19. Altés A, Martino R, Gari M, et al. Heparin-induced thrombocytopenia and heart operation: management with tedelparin. Ann Thorac Surg 1995;59:508-9.
20. Lee L, Liauw P, Ng A. Low molecular weight heparin for thromboprophylaxis during pregnancy in 2 patients with mechanical mitral valve replacement. Thromb Haemost 1996;76(4):628-30.
21. De Paulis R, Fleury JP, Veyssie L, Menasché P, Block G, Piwnica A. Acute massive postoperative atrial thrombosis in a patient undergoing low molecular weight heparin anticoagulation. J Cardiothorac Vasc Anesth 1993;7(3):332-4.
22. Noble S, Peters DH, Goa KL. Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs 1995;49(3): 388-410.
23. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79(1):1-17.